埃格列净治疗心力衰竭相关功能性二尖瓣反流:EFFORT试验
EFFORT试验为多中心双盲随机对照研究,纳入128例NYHA II-III级、EF 35%-50%、功能性二尖瓣反流ERO>0.1 cm²的心衰患者,在指南导向药物治疗基础上加用埃格列净或安慰剂。12个月随访显示,埃格列净组ERO下降幅度显著大于安慰剂组,反流容积、左房容积指数及左室整体纵向应变均显著改善,不良事件无显著差异。
要点
- 埃格列净显著降低功能性二尖瓣反流有效反流口面积(-0.05 vs 0.03 cm²,P<0.001)。
- 埃格列净改善左室整体纵向应变和左房重构,但未显著改变左室容积、EF或NT-proBNP。
- SGLT2抑制剂可考虑用于心衰合并功能性二尖瓣反流患者。
核心结论
- 在心力衰竭合并功能性二尖瓣反流患者中,埃格列净显著改善左室整体纵向应变和左房重构,并减少功能性二尖瓣反流。
研究设计与样本
- EFFORT试验为多中心、双盲、随机对照试验,共随机分配128例患者接受埃格列净或安慰剂,在指南导向药物治疗基础上治疗。
主要发现
- 埃格列净组有效反流口面积下降幅度显著大于安慰剂组(-0.05±0.06 vs 0.03±0.12 cm²,P<0.001)。
- 与安慰剂相比,埃格列净显著降低反流容积11.2 mL(95%CI -16.1至-6.3,P=0.009)。
- 埃格列净显著降低左房容积指数6.0 mL/m2(95%CI -12.16至0.15,P=0.005)。
- 埃格列净显著改善左室整体纵向应变1.44%(95%CI -2.42%至-0.46%,P=0.004)。
- 左室容积指数、射血分数及NT-proBNP水平变化组间无显著差异;严重不良事件在埃格列净组1例(1.6%)、安慰剂组6例(9.2%)(P=0.12)。
关键数值与推荐
- 纳入标准:NYHA心功能II或III级,35%≤射血分数<50%,基线超声示慢性功能性二尖瓣反流有效反流口面积>0.1 cm²。
- 主要终点:12个月随访时功能性二尖瓣反流有效反流口面积较基线的变化。
- 基线特征:平均年龄66±11岁,男性61%,糖尿病13%,房颤51%,使用血管紧张素受体脑啡肽酶抑制剂43%,射血分数42±8%,有效反流口面积0.20±0.12 cm²。
临床怎么用
- 对于心衰合并功能性二尖瓣反流且符合入选标准的患者,可考虑在指南导向药物治疗基础上加用SGLT2抑制剂以改善二尖瓣反流及左室应变。
- 治疗决策需结合患者个体情况,关注左房重构和左室整体纵向应变等指标的变化。
局限性
- 样本量较小(128例),随访12个月,长期疗效与安全性需进一步验证。
- 研究仅纳入射血分数35%-50%的患者,结果不能外推至射血分数<35%或≥50%的人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction. METHODS: The EFFORT trial (Ertugliflozin for Functional Mitral Regurgitation) was a multicenter, double-blind, randomized trial to examine the hypothesis that the sodium-glucose cotransporter 2 inhibitor ertugliflozin is effective for improving MR in patients with HF with New York Heart Association functional class II or III, 35%≤ejection fraction<50%, and effective regurgitant orifice area of chronic functional MR >0.1 cm2 on baseline echocardiography. We randomly assigned 128 patients to receive either ertugliflozin or placebo in addition to guideline-directed medical therapy for HF. The primary end point was change in effective regurgitant orifice area of functional MR from baseline to the 12-month follow-up. Secondary end points included changes in regurgitant volume, left ventricular (LV) volume indices, left atrial volume index, LV global longitudinal strain, and NT-proBNP (N-terminal pro-B-type natriuretic peptide). RESULTS: The treatment groups were generally well-balanced with regard to baseline characteristics: mean age, 66±11 years; 61% men; 13% diabetes; 51% atrial fibrillation; 43% use of angiotensin receptor-neprilysin inhibitor; ejection fraction, 42±8%; and effective regurgitant orifice area, 0.20±0.12 cm2. The decrease in effective regurgitant orifice area was significantly greater in the ertugliflozin group than in the placebo group (-0.05±0.06 versus 0.03±0.12 cm2; P<0.001). Compared with placebo, ertugliflozin significantly reduced regurgitant volume by 11.2 mL (95% CI, -16.1 to -6.3; P=0.009), left atrial volume index by 6.0 mL/m2 (95% CI, -12.16 to 0.15; P=0.005), and LV global longitudinal strain by 1.44% (95% CI, -2.42% to -0.46%; P=0.004). There were no significant between-group differences regarding changes in LV volume indices, ejection fraction, or NT-proBNP levels. Serious adverse events occurred in one patient (1.6%) in the ertugliflozin group and 6 (9.2%) in the placebo group (P=0.12). CONCLUSIONS: Among patients with functional MR associated with HF, ertugliflozin significantly improved LV global longitudinal strain and left atrial remodeling, and reduced functional MR. Sodium-glucose cotransporter 2 inhibitors may be considered for patients with functional MR. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04231331.
引用
- Kang, Park, Shin, et al. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial. Circulation. 2024. PMID: 38690659. doi:10.1161/CIRCULATIONAHA.124.069144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。